Literature DB >> 17678713

Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?

Nathalie Bardin1, Marie Christine Alessi, Francoise Dignat-George, Irene Juhan Vague, Jose Sampol, Jean Robert Harlé, Marielle Sanmarco.   

Abstract

The aim of this study is to get new insight into the relevance of IgG anti-prothrombin antibodies in patients with thrombosis and to determine whether human prothrombin alone (aPT) or complexed to phosphatidylserine (aPS/PT) should be preferentially used for measuring these antibodies by enzyme-linked immunosorbent assay (ELISA). To this end, prevalence of anti-prothrombin antibodies, their characteristics in terms of avidity and heterogeneity, and their relationship with anti-beta2 glycoprotein I antibodies (abeta2GPI) were studied in 152 patients with thrombosis. Patients were divided into two groups according to the presence or absence of antiphospholipid antibodies (aPL), called aPL+ or aPL-, respectively. In the aPL- group (n=90), the prevalence of anti-prothrombin antibodies was substantial (10%) but not significantly different from that of control (5%). In the aPL+ group (n=62), lupus anticoagulant (LA) or anticardiolipin antibodies (aCL) positive, 61% were positive for anti-prothrombin antibodies with no statistical difference between aPT and aPS/PT prevalence (42% vs. 55%, respectively). In the whole thrombotic population, 19% were only aPT and 34% only aPS/PT suggesting the presence of different antibodies. Absorption experiments confirmed the heterogeneity of aPT and aPS/PT. No difference in their avidity was demonstrated. From the aPL+ group, 60 were LA positive. Among them, 18% were negative for abeta2GPI and anti-prothrombin antibodies showing that the detection of these antibodies could not substitute for LA determination. In conclusion, our data show that the screening of the different anti-prothrombin antibodies is not warranted in the aPL+ group since these antibodies do not provide additional information compared to aCL, LA and/or abeta2GPI measurement. Nevertheless, the substantial prevalence of anti-prothrombin antibodies in the aPL- group should be further explored in a large prospective study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678713     DOI: 10.1016/j.imbio.2007.02.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  10 in total

Review 1.  Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.

Authors:  René Y McNall-Knapp
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

2.  Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies.

Authors:  Olga Amengual; Tetsuya Horita; Walter Binder; Gary L Norman; Zakera Shums; Masaru Kato; Kotaro Otomo; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2014-02-05       Impact factor: 2.631

3.  New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Authors:  Savino Sciascia; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

4.  Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.

Authors:  N M Heikal; T D Jaskowski; E Malmberg; G Lakos; D W Branch; A E Tebo
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Lupus anticoagulants in two children--bleeding due to nonphospholipid-dependent antiprothrombin antibodies.

Authors:  Karin Knobe; Ulf Tedgård; Torben Ek; Per-Erik Sandström; Andreas Hillarp
Journal:  Eur J Pediatr       Date:  2012-04-19       Impact factor: 3.183

6.  Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE.

Authors:  Sahwa Elbagir; Giorgia Grosso; NasrEldeen A Mohammed; Amir I Elshafie; Elnour M Elagib; Agneta Zickert; Vivek Anand Manivel; Eleftheria Pertsinidou; Musa A M Nur; Iva Gunnarsson; Johan Rönnelid; Elisabet Svenungsson
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

Review 7.  Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.

Authors:  Pasquale Pignatelli; Evaristo Ettorre; Danilo Menichelli; Arianna Pani; Francesco Violi; Daniele Pastori
Journal:  Haematologica       Date:  2020-01-30       Impact factor: 9.941

8.  Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19.

Authors:  Daniel Bertin; Alexandre Brodovitch; Alexandre Lopez; Robin Arcani; Grace M Thomas; Abdou Beziane; Samuel Weber; Benjamin Babacci; Xavier Heim; Louise Rey; Marc Leone; Jean Louis Mege; Nathalie Bardin
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996

9.  Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value.

Authors:  Polona Žigon; Saša Čučnik; Aleš Ambrožič; Tanja Kveder; Snežna Sodin Šemrl; Blaž Rozman; Borut Božič
Journal:  Clin Dev Immunol       Date:  2013-09-26

Review 10.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.